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ABSTRACT 
 
In addition to the degradation of homologous RNAs through the RNA interference (RNAi) pathway, 
small interfering RNAs (siRNAs) can in some systems induce cytosine methylation and transcriptional 
silencing of homologous promoters. Targeting of HIV-1 by RNAi results in transient suppression of the 
virus through degradation of viral transcripts. In an effort to prolong the suppressive effect of siRNAs 
on productive HIV-1 infection, we targeted conserved tandem NF-κB binding motifs in the viral LTR. A 
21-nucleotide-RNA duplex induced marked and durable (at least 30 days) suppression of productive 
HIV-1 infection in chronically infected MAGIC-5 cells. This suppression is associated with CpG methy-
lation within the 5’LTR and marked reduction of HIV-1 transcription in nuclear run-on assays. We then 
assessed three additional siRNAs targeting other sites within the HIV-1 promoter region. These siRNAs 
suppressed HIV-1 infection to different extents and the degree of suppression correlated with the extent 
of de novo methylation of CpG motifs within the HIV-1 promoter region. These findings indicate that 
HIV-1 can be silenced by an RNA-directed mechanism that suppresses transcription and induces CpG 
methylation. In addition to providing evidence that this RNA-directed DNA methylation is active in 
mammalian cells, this is the first report of prolonged suppression of HIV-1 infection induced by siRNA. 
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INTRODUCTION 
 
RNA interference (RNAi) can suppress a range of patho-
genic  human  viruses  including  poliovirus  (Gitlin  et  al, 
2002), hepatitis virus (Chang and Taylor, 2003; Giladi et 
al, 2003; Randall et al, 2003; Yokota et al, 2003), human 
papillomavirus  (Jiang  and  Milner,  2002)  and  HIV-1 
(Capodici et al, 2002; Coburn and Cullen, 2002; Jacque et 
al, 2002; Lee et al, 2002; Novina et al, 2002; Stevenson, 
2003). Small interfering RNAs (siRNAs) of ~22 nucleo-
tides targeting HIV-1 structural and accessory  genes in-
duce rapid degradation of mRNA containing complemen-
tary sequence, and suppress the production of new virus in 
vitro. The duration of this effect varies from 4 to 7 days 
(Capodici et al, 2002), which may limit the clinical utility 
of RNAi-based therapies. However, prolongation of this 
effect has been achieved using adeno-associated virus or 
lentiviral vectors to deliver stably expressed siRNA. Using 
this approach HIV-1 can be suppressed for between 14 and 
25 days. However, HIV-1 is known to adapt to environ-
mental pressures and rapid selection of siRNA escape mu-
tants has been described in vitro (Boden et al, 2003; Das et 
al, 2004), potentially further limiting the efficacy of treat-
ment modalities based on this approach. 
 
We sought other means to prolong the suppressive effect 
of siRNA that would be less susceptible to the adaptability 
of  HIV-1.  In  plants and  certain  other  model  systems  in  
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mammalian cells (Kawasaki and Taira, 2004; Morris et al, 
2004),  siRNA  targeted  to  promoter  regions  can  induce 
silencing through a mechanism that seems to be distinct 
from RNAi. This mechanism involves transcriptional gene 
silencing  (TGS)  and  cytosine  methylation  (Mette  et  al, 
2000;  Jones  et  al,  2001)  and  has  been  termed  RNA-
directed DNA methylation (RdDM) (Aufsatz et al, 2002; 
Pal-Bhadra et al, 2002). While the exact molecular mecha-
nisms of RdDM are unknown, it is likely to involve cyto-
sine methylation, histone modification and chromatin re-
modeling. Recently, the  RNA-induced initiation  of tran-
scriptional gene silencing (RITS) complex has been impli-
cated in the formation of heterochromatin. RITS contains 
both dicer derived siRNA that guides the complex to an 
homologous  nucleic  acid  sequence,  as  well  as  proteins 
Ago1, Chp and Tas 3 that play a role in the formation of 
heterochromatin.  Together  these  components  have  been 
shown to induce site-specific silencing of centromeric loci 
in fission yeast. The process is associated with methylation 
of histone H3 at Lys 9 (Verdel et al, 2004). However, the 
exact mechanisms by which RITS complex induces and 
maintains site-specific RdDM are yet to be fully delineated 
(Noma et al, 2004; Matzke and Birchler, 2005).  
 
Regardless of the exact mechanisms, once induced, RdDM 
is long lasting and can be passed on across generations in 
plant  systems  (Sijen  et  al,  2001;  Burgers  et  al,  2002; 
Robertson,  2002)  Clearly,  the  harnessing  of  such  pro-
longed  gene silencing would have advantages for  thera-
peutics based on siRNAs. Furthermore, this approach has 
another  theoretical  advantage  when  the  target  is  highly 
adaptable. The adaptability of HIV-1 is related to its high 
turnover  rate  combined  with  the  rate  of  base  pair  mis-
matches  that  occurs  during  reverse  transcription.  With 
transcription halted, opportunities for generation of muta-
tions and, therefore, selection of escape variants should be 
significantly reduced.  Recent reports indicate RdDM and 
short-lived transcriptional gene silencing can be induced in 
mammalian cells by siRNAs (Kawasaki and Taira, 2004; 
Morris et al, 2004). However, in these systems silencing 
required the use of multiple siRNAs simultaneously.  
 
We tested the ability of several siRNAs targeting different 
sequences within the promoter region of HIV-1 to induce 
gene  silencing  and  compared  their  activity  to  that  of  a 
siRNA, which is known act by degradation of homologous 
RNAs. DNA methylation status in the promoter region and 
transcriptional activity was assessed using MAGIC-5 cell 
(CCR5-CXCR4 expressing HeLa/CD4+ cell line) infected 
with HIV-1. 
 
MATERIALS AND METHODS 
 
RNA duplexes  
Double-stranded RNA duplexes were obtained from Dhar-
macon Research Inc (Lafayette, CO).  HIV-1 was targeted 
with the duplexes: 
 
HIV-prom-A siRNA: 
5’-GGGACUUUCCGCUGGGGACTT-3’ (sense) 
5’-GUCCCCAGCGGAAAGUCCCTT-3’ (antisense) 
HIV-prom-B siRNA: 
5’-GGCCCGAGAGCUGCAUCCGGTT-3’ (sense) 
5’-CCGGAUGCAGCUCUCGGGCCTT-3’ (antisense) 
HIV-prom-C siRNA: 
5’-GACUGCUGACAUCGAGCUUTT -3’ (sense) 
5’-AAGCTCGATGTCAGCAGTCTT-3’ (antisense) 
HIV-prom-D siRNA: 
5’-CUGGGGAGUGGCGAGCCCUTT -3’ (sense)  
5’-AGGGCUCGCCACUCCCCAGTT -3’ (antisense) 
HIV- gag siRNA: 
5’-GAUUGUACUGAGAGACAGGCUTT-3’ (sense) 
5’-AGCCTGTCTCTCAGTACAATCTT-3’ (antisense) 
Scrambled siRNA (synthesized with the same overall nu-
cleotide content as HIV-prom-A siRNA): 
5’-CAGCUGGGACGUGUGCCUGTT-3’ (sense) 
 5’-CAGGCACACGTCCCAGCTGTT-3’ (antisense) 
 
HIV infection and transfection of siRNA  
MAGIC-5 cells (2 x 10
5) were infected with the HIV-1 sub-
type B strain NL4-3 (50 pg reverse transcriptase, equivalent 
to 1.3 x 10
6 copies of HIV-RNA) and infection was allowed 
to establish for 5 days. On day 6 cells were detached with 
0.25%  (v/v)  trypsin/1mM  EDTA,  washed  twice  and  re-
seeded at 2 x 10
5 in a 25 ml flask. After 16 hr, the infected 
cells were transfected using a concentration of 530 pM of one 
of the synthesized siRNAs using Oligofectamine (Invitrogen, 
Mount Waverley, Australia) according to the manufacturer’s 
instructions. Cultures were maintained according to standard 
protocols (Aldovini and Walker, 1990). Briefly, 25cm
2 flasks 
were seeded with 2 x 10
5 cells every 4-6 days. Cultures with 
high level HIV-replication were supplemented with fresh un-
infected cells at each passage. In one set of experiments a 
range  of  viruses  were  used  including,  HIV-1  laboratory 
strains HIV-1 IIIB, RF and HIV-2 CBL-20, as well as two 
primary  isolates derived from patients, failing  combination 
anti-retroviral therapy (Kaufmann et al, 2001). 
 
Viral quantification  
Reverse transcriptase activity in culture supernatants was 
determined as previously described (Suzuki et al, 1993). 
HIV-1 mRNA was quantified using a real-time RT-PCR 
assay specific for HIV-gag.  RT-PCR reactions were per-
formed  with  SuperScript  One-step  RT-PCR  (Invitrogen) 
using 0.4 µM of both sense and anti-sense primers, and 0.1 
µM of sequence-specific fluorogenic Taqman probe. Stan-
dard curves were constructed using genomic HIV plasmid 
pNL4-3  for  HIV-1  and  a  TA-cloned  PCR  fragment  of 
beta-actin  (Invitrogen,  Mount  Waverley,  Australia).  The 
primers and probes used were: 
 
HIV-gag sense primer: 
5’-AGTGGGGGGACATCAAGCAGCCATGCAAAT-3’ 
HIV-gag antisense primer: 
5’-TACTAGTAGTTCCTGCTATGTCACTTCC-3’ 
HIV-gag detection probe: 
5’-FAM-
ATCAATGAGGAAGCTGCAGAATGGGATAG-
TAMRA-3’ 
Beta-actin sense primer: 
5’-TCACCCACACTGTGCCCATCTACGA-3’ 
Beta-actin anti-sense primer: 
5’-CAGCGGAACCGCTCATTGCCAATGG-3’ 
HIV-gag detection probe: 
5’-FAM-ATGCCCTCCCCCATGCCATCCTGCG- 
TAMRA-3’  
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Proviral DNA was detected by PCR assay using the same 
HIV-gag specific primers. ICAM-1 mRNA quantification 
was performed by real-time PCR using primer set: 
 
ICAM-1 sense primer: 
5’-CCGAGCTCAAGTGTCTAAAG-3’ 
ICAM-1 antisense primer: 
5’-TGCCACCAATATGGGAAGGC-3’ 
 
The reaction conditions were the same as for the amplifi-
cation of HIV-gag, except for the addition of 10,000 times 
dilution of Sybr Green used instead of the flurogenic probe 
(Molecular Probes, Eugene, OR, USA). Product was quan-
tified  by  the  threshold  cycle  number.  Amplification  of 
product  of correct size  was  confirmed by  ethidium bro-
mide stained gel analysis.  
 
Histochemical analysis 
Activated  caspase-3  was  identified  using  immunohisto-
chemistry  on  MAGIC-5  cells  grown  in  glass  chamber 
slides.  Cells  were  fixed  in  acetone/methanol,  permeabi-
lised with  0.025% (v/v) Triton-X 100 and blocked with 
5% (v/v) normal goat serum. Cells were then stained with 
polyclonal caspase-3 antibody (1/400; Becton-Dickinson, 
Palo Alto, CA) and monoclonal vimentin antibody (1/200; 
Becton-Dickinson, Palo Alto, CA) for 1 hour at 37˚C. Fol-
lowing washing, cells were then incubated with the appro-
priate secondary antibodies (goat anti-mouse Alexa 488 or 
goat anti-rabbit Alexa 594 (Molecular Probes).  Nuclear 
staining  was  performed  using  DAPI  (1µg/ml)  (Sigma-
Aldrich, Castle Hill, Australia). 
  
Methylation analyses  
Genomic  DNA  was  extracted  from  siRNA  transfected 
HIV-1  infected  MAGIC-5  cell  cultures.  Methylation  of 
CCGG site at –146 upstream of the transcription start site 
was determined by restriction enzyme digest of DNA by 
HpaII (New England BioLabs, Beverly, MA), followed by 
PCR  amplification  using  a  primer  set  of  5'-
CTGAGAGAGAAGTGTTAGAGTGGAGGTTTG-3’ and 
5'-TTTTTTCCCATTTATCTAATTCTCC-3'.  Prior  to 
restriction  enzyme  digestion,  the  amount  of  input  DNA 
was normalized to 3000 copies of HIV-1.  High resolution 
analysis of the methylation status of CpG sites in the HIV-
1 5’LTR was determined using bisulfite sequencing (Clark 
et al, 1994).  Bisulfite-modified DNA was used in a nested 
PCR amplification with the first primer set: 
 
Sense primer: 
5'-YTGAGAGAGAAGTGTTAGAGTGGAGGTTTG-3’ 
Antisense primer: 
5'-TTTTTTCCCATTTATCTAATTCTCC-3' 
And, the second primer set: 
Sense primer: 
5'-YTGAGAGAGAAGTGTTAGAGTGGAGGTTTG-3' 
Antisense primer: 
5'-TCTCRCACCCATCTCTCTCCTTC-3’ 
 
PCR fragments were TA cloned and at least 10 colonies 
were  sequenced.  To  confirm  the  methylation-related  si-
lencing  effect,  the  methylation  inhibitor,  5-azacytidine 
(Sigma) was added in varying concentrations to cultures 6 
days after transfection with siRNA. After 30 hr, mRNA 
was extracted and  subjected to real-time analysis as  de-
scribed above.  
 
Analysis of transcriptional activity  
Nuclear run-ons were performed essentially as described 
(Greenberg  and  Bender,  1997)  on  the  nuclei  isolated  3 
days post transfection with siRNA. MAGIC-5 cells were 
infected for 3 days prior to the transfection.  HIV-1 pol 
probes were synthesized by PCR amplification of HIV-1 
DNA with the primer set: 
 
pol-F: 
5’-GCTTCCACAGGGATGGAAAGG-3’ 
pol-R: 
5’-GGCTCTTGATAAATTTGATATGTCCATTGG-3’ 
 
Beta-actin probes were prepared similarly using primer set: 
 
actin-F: 
5’-TCACCCACACTGTGCCCATCTACGA-3’ 
actin-R: 
5’-CTCCAACCGACTGCTGTCACCTTCAC-3’ 
 
Both DNA fragments were immobilized on a nylon mem-
brane  (Zeta-Probe  Membrane,  Bio-Rad,  Hercules,  CA).  
Hybridization was carried out for 16 hr at 42
˚C using UL-
TRAhyb,  (Ambion,  Austin,  TX),  followed  by  washing 
with 5xSSC and 1xSSC.  The membrane was scanned in a 
PhosphorImager (Molecular Dynamics, NJ). 
 
RESULTS 
 
Prolonged suppression achieved by a siRNA targeting 
HIV-1 promoter  
We first asked if a siRNA targeted to the HIV-1 promoter 
could induce durable, potent suppression and transcrip-
tional silencing of the HIV-1 provirus in cultured cells. 
We  designed  a  21  nucleotide  siRNA  (HIV-prom-A 
siRNA) with a sequence identical to a site in U3 region 
of the HIV-1 LTR, at ~-100 with respect to the transcrip-
tional  start  site  (Figure  1A).  This  region  contains  two 
NF-κB binding sites arranged in tandem separated by a 
four-nucleotide gap and is highly conserved among dif-
ferent HIV-1 subtypes. The nucleotide sequence within 
the  NF-κB  binding  motif  appears  to  be  optimized  for 
HIV-1 gene expression and differs from that found in the 
promoter  regions  of  human  genes  (Chen-Park  et  al, 
2002).  The target sequence  of  HIV-prom-A  siRNA in-
cludes  the  5’  NF-κB  binding  site, the  four  intervening 
nucleotides and the first six nucleotides of the next NF-
κB binding site. A BLAST search of the human genome 
failed to identify sequences homologous to HIV-prom-A 
siRNA, with the most similar sequence sharing 17 out of 
21 bases, suggesting that there are no significant endoge-
nous targets for HIV-prom-A siRNA. 
 
To assess the effects of HIV-prom-A siRNA, we initially 
used MAGIC-5 cells in which productive infection with 
the HIV-1 molecular clone NL4-3 was established 7 days 
prior  to  transfection  with  siRNA. New  virus  production 
was quantified by reverse transcriptase (RT) levels in cul-
ture supernatants. Significant levels of RT at day 6 follow-
ing  infection  confirmed  established,    productive  NL4-3  
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Figure 1. A siRNA targeting the HIV-1 promoter inhibits HIV-1 replication: (A) Location of sequence targeted by the siRNA.  The 
positioning of NF-κB binding sites in the 5’LTR are indicated by red dots; the blue shading represents the target sequence of the 
siRNA (HIV-prom-A); the underlining indicates the sequence of the tandem NF-κB binding motifs. (B) Effect of short siRNAs on 
the time course of HIV-1 (NL4-3) production in MAGIC-5 cells: At day 7 siRNAs were transfected into productively infected cells 
(indicated by arrow). Reverse transcriptase (RT) levels are shown for cultures transfected with HIV-prom-A siRNA (blue triangle) 
and scrambled siRNA (red circle), mock transfected cells (green square), and uninfected cells (black square).  (C) HIV-1 proviral 
DNA is present in HIV-prom-A siRNA transfected cells. Provirus was detected by PCR amplification of 154bp fragment of HIV-1 
gag gene from DNA extracted from MAGIC-5 cells 25 days after infection. NC indicates non-infected MAGIC-5 cells. (D) Abroga-
tion of HIV-1 protein synthesis induced by HIV-prom-A siRNA shown by western blot analysis of HIV-Gag-p24, Gag precursor 
protein p55 and beta-actin expression in cell lysates of MAGIC-5 cells 10 days after infection with NL4-3. (E) HIV-1 RNA is mark-
edly reduced in the nuclei of cells transfected with HIV-prom-A siRNA. Viral RNA was quantified by real time PCR in the nuclei 
isolated from MAGIC-5 cells either 10 days or 20 days after infection. HIV viral RNA copy number is shown as copies per 1000 
copies of beta-actin. NC indicates non-infected MAGIC-5 cells.
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infection prior to transfection with siRNA. By day 20 after 
infection (day 13 post-transfection), viral RT levels were 
reduced over 1000-fold when compared to either mock 
transfected cultures or cultures transfected with a scram-
bled siRNA (Figure 1B). This suppression of productive 
infection was maintained for at least 30 days after a sin-
gle  transfection  of  HIV-prom-A  siRNA.  Proviral DNA 
could still be detected within cell cultures 25 days after 
infection (18 days after transfection), indicating that al-
though productive infection and viral turnover were ab-
sent, the cells retained HIV-1 provirus (Figure 1C). No 
variation was detected in the HIV-prom-A siRNA target 
sequence  at  day  38  post  infection  (data  not  shown). 
Western blot analysis showed HIV-1 specific viral pro-
tein p24 and precursor p55 were markedly decreased in 
cultures treated with HIV-prom-A siRNA at day 10 after 
HIV  infection  (day  3  post-transfection)  (Figure  1D). 
Real-time  PCR  analysis  showed  HIV-1  RNA  levels  in 
the nuclei isolated from MAGIC-5 cells at day 20 after 
HIV infection (day 13 post-transfection) were over 1000 
fold lower in HIV-prom-A siRNA treated cultures com-
pared to cultures treated with mock siRNA (Figure 1E). 
Although there is some apparent degree of suppression of 
HIV-RNA  in  the  cultures  transfected  with  scrambled 
siRNA,  these,  presumably  non-specific  effects,  are  ap-
proximately two orders of magnitude less than the effect 
of the HIV-prom-A siRNA.   
 
The inhibition of productive HIV-1 infection was sup-
ported  by  a  number  of  other  observations.  Productive 
infection with NL4-3 in MAGIC-5 cells is characterized 
by increasing syncytia formation, caspase-3 activation in 
multinuclear  cells  and  apoptotic  cell  death.  In  vitro, 
HIV-1 infection of this cell line is characterised by ele-
vated  caspase-3  activity.    We  therefore  monitored  the 
effect of HIV-prom-A siRNA on caspase-3 activity as a 
way  assessing  the  effects  of  cell  associated  infection. 
Transfection  of  infected  cultures  with  HIV-prom-A 
siRNA was associated with reductions of each of these 
parameters  to  levels  seen  in  non-infected  cells,  while 
levels in mock or scrambled siRNA transfected cultures 
appeared  comparable  to  un-manipulated  infected  cul-
tures (Figure 2). HIV-prom-A siRNA treatment did not 
alter  the  cell  surface  expression  of  proteins  CD4  or 
CCR5, or the rate of MAGIC-5 cell proliferation (data 
not shown).  
 
Suppression of other HIV-1 isolates by HIV-prom-A 
siRNA 
We investigated whether HIV-prom-A siRNA could in-
duce similar effects in cultures infected with other iso-
lates of HIV-1. The effect of this siRNA was tested on 
two other laboratory strains of HIV-1 (IIIB/LAI and RF) 
and two clinical isolates (CL-1 and CL-2) derived from 
patients who had failed combined anti-retroviral therapy 
(Suzuki et al, 2001). In these set of experiments we in-
fected MAGIC-5 cells with HIV isolates 5 hours prior to 
transfection with siRNA. Under these experimental con-
ditions, at day 7 after infection with the HIV-1 isolates 
NL 4-3, IIIB/LAI, RF, CL-1 and CL-2, RT activity was 
reduced by  900,  200,  150,  1500  and  150  fold,  respec-
tively, in MAGIC-5 cells transfected with HIV-prom-A 
siRNA compared to mock controls (Figure 3).  
A: 
 
 
 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Prom-A siRNA inhibits syncytia formation and host 
cell death. (A) HIV-prom-A siRNA reduces syncytium forma-
tion in infected MAGIC-5 cells (Phase-contrast microscopy of 
MAGIC-5 cells at 200X magnification).  The time points indi-
cate days after infection (see Fig. 1B).  The prominent syncytia 
seen in the mock-transfected cells are absent from the HIV-
prom-A siRNA transfected culture.  (B) Caspase-3 activity is 
reduced to normal levels in HIV-1 infected cells by transfection 
of HIV-prom-A siRNA. Caspase-3 activity (red) is detected in 
MAGIC-5 cells transfected with siRNA 7 days earlier.  DAPI 
staining (blue) outlines the nuclei, and cell structure was high-
lighted by Vimentin staining (green). NC indicates non-
infected MAGIC-5 cells. 
 
 
HIV-prom-A siRNA suppression is HIV-1 specific 
We  then  checked  the  specificity  of  the  suppression  in-
duced  by  HIV-prom-A  siRNA by  studying its effect  on 
productive  HIV-2  infection  and  expression  of  ICAM-1. 
Both have single NF-κB binding motifs in their promoter 
regions (Figure 4A). In HIV-2 the single NF-κB binding 
motif  is  homologous to that  of  HIV-1, but  the flanking 
sequence is not, resulting in a five nucleotide difference 
from the HIV-prom-A siRNA sequence. The single NF-κB 
binding motif of ICAM-1 differs by 3 nucleotides from the 
NF-κB  binding  motif  of  HIV-1  and  also  differs  in  the 
flanking  regions,  resulting  in  a  9  nucleotide  difference 
from HIV-prom-A siRNA. MAGIC-5 cells were infected 
with laboratory strain HIV-2  CBL-20,  prior to being  trans- 
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Figure 3. A siRNA inhibits replication of 5 different strains 
of HIV-1.  Graphs show kinetics of viral replication following 
transfection of HIV-prom-A siRNA into MAGIC-5 cells 5 
hours after infection with laboratory strains of HIV-1 (NL 4-
3, IIIB/LAI, and RF) or two clinical isolates (CL-1 and CL-2) 
from patients failing multiple combination anti-retroviral 
regimens (Kaufmann et al, 2001).  HIV infection was allowed 
to establish during a 5 hour incubation. Thereafter, cells were 
transfected with HIV-prom-A siRNA.  Infection of MAGIC-5 
cells was confirmed by HIV DNA-PCR (data not shown).  
Reverse transcriptase (RT) levels are shown for cultures 
transfected with HIV-prom-A siRNA (blue triangle), mock 
transfected cells (red circle), and uninfected cells (black 
square). Black arrow indicates timing of transfection. 
A: 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Specific suppression achieved after transfection of 
prom-A siRNA.  (A) The promoter regions of HIV-1, HIV-2, and 
ICAM-1 are aligned. Sequence corresponding to HIV-prom-A 
siRNA highlighted in blue.  Non-homologous bases in HIV-2 
and ICAM-1 are indicated in red. Underlining indicates the NF-
κB binding sites. (B) HIV-prom-A siRNA does not inhibit HIV-2 
infection. Histogram shows RT levels 8 days after transfection 
with siRNAs, 8hours after infection of MAGIC-5 cells with labo-
ratory stain HIV-2 CBL-20.  No marked difference was observed 
among cultures transfected with HIV-prom-A, scrambled siRNA 
or mock transfection. NC indicates non-infected MAGIC-5 cells. 
(C) ICAM-1 gene expression is not affected by HIV-prom-A 
siRNA transfection. MAGIC-5 cells were infected with HIV-1 
molecular clone NL4-3 for 5 hours followed by transfection with 
siRNAs.  Expression levels of HIV-1 gag and ICAM-1 mRNA at 
day 3 post infection are shown in the histograms normalized to 
10
3 copies of β-actin mRNA. Mean and standard deviations were 
obtained from three different experiments. Mock: transfection 
with lipofectamine only, NC: non-infected MAGIC-5 cells. 
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fected. HIV-prom-A siRNA did not induce any suppres-
sion of HIV-2 infection following 8 days of culture (Fig-
ure  4B).  Transfection  of  HIV-prom-A  siRNA  into 
MAGIC-5  cells  infected  with  NL  4-3  did  not  alter 
ICAM-1 expression despite suppressing HIV-1 infection 
(Figure 4C). 
 
Transcriptional  gene  silencing  is  induced  by  HIV-
prom-A siRNA 
Nuclear run-on assays provide a direct assessment of tran-
scription  and  can  distinguish  transcriptional  from  post-
transcriptional effects. Run-on assays of the nuclei isolated 
from infected cultures 3 days after transfection  of HIV-
prom-A siRNA indicate that transcription of HIV-1 was 
fully suppressed (Figure 5). By contrast, HIV-1 transcrip-
tional activity was evident in cultures treated with scram-
bled siRNA or mock transfection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Nuclear run-on assays indicate transcriptional sup-
pression by HIV-prom-A siRNA. Results of a representative 
assay (n = 3) in which cDNAs were immobilized on nylon 
membranes, and probed with RNA extracted from isolated the 
nuclei after run-on transcription with 
32P-labelled UTP (guide 
strip at bottom; blank: no cDNA).  De novo transcription of 
HIV-1 is evident in the mock-transfected culture and the cul-
ture transfected with the scrambled siRNA. HIV-1 transcription 
is absent from uninfected cells (NC) and cells transfected with 
HIV-prom-A siRNA. 
 
 
Differential  levels  of  suppression  by  three  other 
siRNAs targeting HIV-1 promoter 
We  designed  three  additional  siRNAs  (HIV-prom-B,  C 
and D siRNAs) targeting sequences containing CpG sites 
in regions adjacent to that targeted by HIV-prom-A siRNA 
(Figure 6A) and assessed the relative efficacy of each of 
these constructs under the same cell culture conditions. As 
a further comparator we included a siRNA targeting a gag 
sequence, previously reported to be an effective inhibitor 
of HIV-1 replication acting by PTGS (Novina et al, 2002). 
The kinetics of viral suppression varied among the siRNAs 
tested (Figure 6B). By day 18 after infection (day 11 post-
transfection) RT levels were reduced over 1000-fold in the 
cultures transfected with either HIV-prom-A or B siRNAs, 
when compared to mock transfected cultures. This degree 
of suppression was maintained until at least day 38 after 
infection  (day  31  post-transfection)  with  HIV-prom-A 
siRNA, whereas there was evidence of some viral produc-
tion  by  day  38  with  HIV-prom-B  siRNA.  HIV-prom-C 
siRNA was able to suppress viral production transiently 
until day 14 after infection (day 7 post transfection) and 
HIV-prom-D siRNA did not induce any significant viral 
suppression. HIV-gag siRNA, suppressed viral production 
until day 14 after infection (day 7 post transfection), but 
thereafter viral production approached levels seen in mock 
transfected  cultures.  The  extent  of  inhibition  of  HIV-1 
replication  induced  by  this  siRNA  in  these  experiments 
was similar in magnitude and duration to that previously 
reported  (Novina  et  al,  2002).    Cell  associated  proviral 
HIV-1 DNA was detectable up to and including day 38 in 
all cultures (Figure 6C).  
 
RdDM  is  induced  by  siRNAs  targeting  HIV-1  pro-
moter 
The suppression of HIV-1 induced by HIV-prom siRNAs 
could  have  occurred  through  either  a  transcriptional 
(RdDM) or a post-transcriptional (RNAi) mechanism, but 
persistence of the effect and the run on data suggested to 
us  that  these  siRNAs  may  have  induced  transcriptional 
silencing  through  RdDM.  To  investigate  methylation  of 
CpGs in the HIV-1 LTR, we treated DNA, extracted from 
cultures at 14, 21, and 38 days after infection (days 7, 14, 
and 31 post-transfection respectively) with the methylation 
sensitive restriction enzyme HpaII (Figure 6A and 7A). A 
PCR amplicon of the HIV-1 5’-LTR was generated from 
HpaII-digested DNA derived from HIV-prom-A, B, and D 
siRNA-treated cells, indicating methylation of CpGs at the 
HpaII site at each of the time points sampled (Figure 7A).   
On the other hand, there was no evidence of methylation at 
this  site  following  transfection  with  scrambled,  gag  or 
HIV-prom-C  siRNA  constructs  or  in  mock  transfected 
cultures.  PCR amplification of this region prior to diges-
tion by HpaII generated bands in all infected cultures re-
gardless  of  treatment  confirming  the  presence  of  HIV 
DNA in these cells at all time points, independently con-
firming the data regarding the presence of provirus gener-
ated by PCRs of the gag  region (Figure 6C).   
 
To  explore  the  induction  of  methylation  by  HIV-prom 
siRNAs in more depth, we sequenced bisulfite-treated ge-
nomic DNA extracted from the MAGIC-5 cultures 38 days 
after initial transfection (Figure 7B). Transfection of HIV-
prom-A siRNA was associated with cytosine DNA methy-
lation at 6 of 7 CpGs sites studied within the LTR, includ-
ing the CpG site in the target sequence (position –97 rela-
tive to the transcription initiation site of the TAR region; 
Figure 5A) in 10/10 clones.  Transfection of HIV-prom-B 
siRNA was associated with DNA methylation at 5  of  7 
CpG sites in at least 8/10 clones at each site. HIV-prom-C 
and HIV-prom-D siRNAs induced less intense methylation 
at fewer sites (Figure 7B). No significant CpG methylation 
was seen in mock, HIV-gag siRNA or scrambled siRNA 
transfected cultures. In all cases, including HIV-prom-C, 
the methylation status at the CpG site at –146, as deter-
mined by HpaII digestion was consistent with that demon-
strated by bisulfite sequencing. It is notable that all four 
promoter-targeted  siRNAs  induced DNA methylation at
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Figure 6. Effect of six short siRNAs on productive HIV-1 infection including 4 siRNAs targeting HIV-1 promoter region and 
siRNA HIV-gag, which is known act as PTGS. (A) The sequences within HIV-1 5’LTR targeted by HIV-prom-A-D siRNAs are 
indicated by highlighting. HIV-prom-B siRNA target sequence includes CpG sites at –159 and –146, HIV-prom-C siRNA target 
sequence includes CpG at –120, and HIV-prom-D siRNA target sequence includes CpG at –48.  CpGs within the 5’LTR of 
HIV-1 are indicated by emboldened text. Nucleotide numbering is relative to the transcription start site and sequence is that of 
HIV-1 strain NL4-3. Each siRNA contains at least one CpG site. (B) Effect of siRNAs on the time course of HIV-1 (NL4-3) 
production in MAGIC-5 cells. At day 7 post-infection siRNAs were transfected into the cells (indicated by arrow). Reverse 
transcriptase (RT) levels are shown for cultures transfected with HIV-prom-A, B, C, D, HIV-1-gag, and scrambled siRNAs as 
indicated in the figure legend. (C) HIV-1 proviral DNA is present in cultures transfected with HIV-prom siRNAs regardless of 
whether infection is productive or not.  PCR amplification of proviral DNA extracted from MAGIC-5 cells 38 days after infec-
tion (Figure 6B). The amplified region is a 154bp fragment of the HIV-1 gag gene. NC indicates non-infected MAGIC-5 cells. 
 
the  CpG  sites  contained  within  their  target  sequences.   
Furthermore, bisulfite sequencing revealed the same pat-
tern of CpG methylation at day 3 post-transfection in cul-
tures  treated  with  HIV-prom-A  siRNA,  suggesting  the 
methylation  patterns  seen  are  established  early  and  are 
then maintained (data not shown). 
 
To further explore  the link  between cytosine  methylation  
and the reduction in virus production, we treated cells with 
the methylation inhibitor 5-azacytidine (5-aza-C), and then 
determined  intracellular  viral  RNA  levels  by  RT-PCR.  
Treatment with 5-aza-C for 30 hours partially reversed the 
suppression  induced  by  HIV-prom-A  siRNA,  increasing 
HIV-RNA production by  2-25 fold (Figure 6D).  These 
data indicate increased viral turnover is related to chemical 
inhibition of DNA methylation. 
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Figure 7. HIV-prom-A siRNA induces CpG methylation of the HIV-1 LTR and transcriptional suppression. (A) The DNA from 
HIV-1 provirus in cells transfected with HIV-prom-A, B, and D siRNA is protected from digestion with the methylation-sensitive 
restriction enzyme HpaII.  DNA was extracted from HIV-1 infected cells at 14, 21, and 38 day after infection (day 7, 14, and 31 
post-transfection respectively), digested with HpaII and subjected to PCR using primers with binding sites denoted by arrows 
above the map. Nucleotide numbering is relative to the transcription initiation site. The downstream primer is located outside the 
LTR, so that this primer set specifically amplifies only the 5’ LTR. The restriction enzyme HpaII is methylation sensitive such 
that it will not cut if the CpG in the CCGG recognition site is methylated. HpaII cuts this region of HIV-1 at the single CpG site 
at position -146 (labeled HpaII); PCR amplification will occur only if the DNA between the primer binding sites has not been cut. 
W/O indicates that DNA has not been subjected to HpaII digestion. Amplification of proviral DNA from mock-transfected cells 
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was abrogated by pre-digestion with HpaII, indicating that it was unmethylated. By contrast amplification from HpaII-digested 
DNA is successful from the cultures transfected with HIV-prom-A, B, and D siRNA, indicating that the HpaII sites were methy-
lated. (B) Bisulfite allelic sequencing of the 5’ LTR of the HIV-1 provirus at 38 day after infection. Bisulfite-modified genomic 
DNA was PCR amplified with nested primers specific for the bisulfite-converted sequence (see Methods) and ligated into a plas-
mid vector; at least 10 individual plasmid clones were sequenced.  Methylated cytosines are spared from bisulfite conversion, 
while unmethylated cytosines are converted to uracils. The figure shows sequences of individual clones as horizontal lines, with 
the CpGs numbered as in Figure 6A; unfilled boxes are unmethylated CpGs, and filled boxes are methylated CpGs. (C) The de-
methylating agent 5-azacytidine (5-aza-C) partially restores HIV transcription in cells previously transfected with HIV-prom-A 
siRNA. Real-time PCR amplification of the gag region from RNA was used to detect productive infection in MAGIC-5 cells.  Six 
days after transfection with siRNA cells were treated with 5-aza-C at the indicated concentrations for 30 hours. The positive con-
trol (PC) was a culture in which no siRNA was transfected, and the negative control (NC) was uninfected cells. The results are 
shown as HIV RNA copy number per 1000 copies of beta-actin. 
 
 
DISCUSSION 
 
Taken together, these findings derived from four different 
siRNAs  targeting  HIV-1  promoter  region,  suggest  that 
these duplexes induce RdDM of the 5’LTR of HIV-1 to 
varying extents, both in terms of number of CpG sites in-
volved and the density of the methylation that occurs at 
each site. The degree and density of methylation in turn 
correlates with the effectiveness of viral suppression. Me-
thylation includes the CpG sites within the sequence ho-
mologous to the siRNA but extends to adjacent CpG sites.  
Spreading of DNA methylation to adjacent CpG sites has 
been observed previously, most commonly in plants (Jones 
et al, 1999; Van Houdt et al, 2003; Xie et al, 2004; Wang 
and  Metzlaff,  2005),  but  also  in  mammalian  cells 
(Kawasaki and Taira, 2004).  The time course of suppres-
sion contrasts markedly with transient suppression of HIV-
1  production  induced  by  transfection  of  siRNAs  which 
target  HIV-1  structural  or  regulatory  genes  and  act  by 
PTGS (Capodici et al, 2002; Novina et al, 2002).  
 
Although  some  similarities  exist  between  plants  and 
mammals in the enzyme systems involved in the mainte-
nance of DNA methylation at CpG sites (Cao et al, 2003; 
Bender, 2004), recent publications suggest that an enzyme 
essential for de novo RNA-directed DNA methylation in 
plants,  a  subunit  of  RNA  polymerase,  is  not  found  in 
mammalian cells, but is unique to plants and there is no 
clear homologue in mammalian cells (Kanno et al, 2005).   
However, current reports demonstrate that DNA methyla-
tion  can  be  induced  by  siRNA  in  mammalian  cells 
(Kawasaki and Taira, 2004; Morris et al, 2004; Castanotto 
et al, 2005). Clearly, the underlying pathways involved in 
this process still require further elucidation. 
 
In the case of the most effective of the constructs tested 
here,  CpG  methylation  is  induced  early  and  then  main-
tained  over  the  period  of  observation.  The  potency  and 
persistence of the effect is related to the degree and pattern 
of  CpG  methylation induced.  The  onset  of  the effect  is 
rapid as indicated by the early suppression of viral protein 
and RNA expression, the early inhibition of transcription 
as demonstrated by the run on assays and the early onset 
of de novo methylation as demonstrated by the HpaII di-
gests. The constructs clearly vary in their potency, but the 
determinants of potency are still to be elucidated. The ef-
fect is specific, it is abrogated by variation in the target 
sequence, but is maintained if the target sequence is highly 
homologous to the duplex transfected. This observation is 
similar  to,  and  extends,  the  well  described  ability  of 
siRNAs  to  induce  prolonged  TGS  in  plant  systems 
(Wassenegger,  2000)  and  supports  some  recently  pub-
lished data regarding this phenomenon in mammalian cells 
(Kawasaki and Taira, 2004; Morris et al, 2004). However, 
in  both  these  later  reports  the  silencing  was  relatively 
short-lived  (up  to  8  days)  even  when  multiple  siRNAs 
were used in combination (Kawasaki and Taira, 2004).   In 
our hands HIV-prom-A and -B siRNAs induced prolonged 
suppression of themselves, in the absence of any require-
ment for combination.  
 
The  stability  of  suppression  induced  by  HIV-prom-A 
siRNA may result from methylation of the LTR and inhi-
bition of transcription. Although this mechanism is well 
described  in  plants  and  similar  observations  have  been 
made in centromeric chromatin in yeast, the precise mo-
lecular  events  producing  the  effect  are  not  well  under-
stood.  It  remains  unclear  how  these  promoter  targeted 
siRNA induce CpG methylation and that how is this main-
tained and extended beyond the target sequence. However, 
hints as to the possible mechanism can be derived from 
observations in plants, yeast and mammalian cells.  Firstly, 
it is known that the induction of methylation at CpG sites 
in targeted promoter regions after transfection of siRNA is 
dependent upon DNMT (Kawasaki and Taira, 2004). More 
recently it has been hypothesized that in  yeast initiation 
and extension of de novo CpG methylation is dependent 
upon the  RITS complex.  This complex consists  of  both 
dicer  derived  siRNA  and  a  range  of  proteins  including 
Chp1,  Tas3  and  Ago1  (Schramke  and  Allshire,  2003; 
Noma et al, 2004; Verdel et al, 2004). All these proteins 
are associated with silenced centromeric heterochomatin in 
yeast. Furthermore, once binding is initiated RITS com-
plexes  can  act  on  adjacent  sequences.  The  stability  of 
RITS association with heterochomatin appears to be de-
pendent  upon  Histone  3-Lys-9  methylation  and  this  is 
critical for its role in TGS (Rea et al, 2000; Zilberman et 
al, 2003; Kawasaki and Taira, 2004).  Importantly, a large 
number of the components of the RITS complex and its 
associated machinery seem to be identical to those used by 
the RISC (RNA-induced silenced complex) in the process 
of siRNA induced PTGS (Motamedi et al, 2004; Noma et 
al,  2004;  Verdel  et  al,  2004).  The  precise  relationships 
between the actions of promoter targeted siRNA, the RITS 
complexes, DNA compaction and DNA methylation in the 
promoter region still require further elucidation.  
 
The process of TGS by the RITS complex is dependent 
upon an effective nucleation site (Noma et al, 2004).  This 
site is determined by sequence homology with the siRNA  
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included in the RITS complex. It is conceivable that si-
lencing  efficiency  will  depend  on  the  ability  of  the tar-
geted  sequence  to  act  as  an  effective  nucleation  site. 
Therefore, the efficiency of HIV-prom-A and -B siRNAs 
to suppress gene expression relative to those siRNAs tar-
geting other promoter regions may reflect inherent, as yet 
to be described differences in targeted promoter regions.   
 
Further support for CpG methylation of the 5’LTR being 
a plausible component of transcriptional gene silencing of 
HIV-1 comes from the literature concerned with retroviral 
latency. The 5’LTR of HIV-1 plays a critical role in the 
regulation  of  proviral  transcription  containing  sites  that 
bind a range of viral and cellular transcription factors in-
cluding NF-κB (Nabel and Baltimore, 1987; Perkins et al, 
1993; Okamoto et al, 1996). Previous studies have dem-
onstrated that methylation of CpG sites within the 5’LTR 
is  associated  with  inhibition  of  viral  transcription 
(Gutekunst et al, 1993).  HIV-1 latency in transgenic mur-
ine models is associated with CpG methylation within the 
5’LTR (Tanaka et al, 2003). Conversely, demethylation of 
these sites and histone acetylation within the 5’ LTR re-
gion is associated with viral activation (Lusic et al, 2003). 
Furthermore, true viral latency of the related retrovirus, 
human T-cell leukemia virus type 1 (HTLV-1), is associ-
ated with methylation of CpG sites within the 5’LTR of 
that virus (Koiwa et al, 2002). Thus RdDM may provide a 
mechanism by which latency of the HIV-1 provirus can 
be induced. The continued presence of proviral DNA in 
the absence of productive infection in the cultures trans-
fected with HIV-prom-A siRNA, along with the methyla-
tion data suggest that these siRNAs are inducing a state 
akin to viral latency. 
 
While targeting HIV-1 structural or accessory  genes by 
siRNA induces rapid degradation of viral RNA, the dura-
tion of suppression is short lived (Capodici et al, 2002). 
The duration of this effect can be extended up to 14 - 25 
days  using  recombinant  adeno-associated  or  lentiviral 
vectors to deliver siRNA. However, these approaches still 
compromised  by  the ability  of  the virus  to  evolve as  a 
result of changes in environmental pressures. Viral eva-
sion of this type of suppression may also be mediated by 
non-mutational  mechanisms.    Recently,  Tat  has  been 
shown to act as a suppressor of dicer activity, inhibiting 
the  processing  of  shRNA  into iRNAs  (Bennasser et al, 
2005).  Another  possible  mechanism  of  RNA  induced 
suppression  of  HIV  replication  has  recently  been  de-
scribed. Single stranded microRNA, derived from HIV-
nef    sequences  found  in  long  term  non-progresses,  can 
induce  short  term  (48h)  translational  repression  of  Nef 
expression (Omoto et al, 2004). 
 
The advantages of RdDM over a mechanism that degrades 
RNA after transcription are not limited the half-life of its 
effect. The high mutation rate of HIV-1, stemming from 
its non-proof reading reverse transcriptase and high repli-
cation rates, confers an ability to adapt to environmental 
pressures, including anti-retroviral drugs and immune re-
sponses (Miller and Larder, 2001; Klenerman et al, 2002), 
and this can result in eventual loss of efficacy of an RNAi 
inducing siRNA (Boden et al, 2003). Transcriptional sup-
pression by RdDM reduces viral turnover markedly, and if 
no new copies of RNA are being made, then the viral RT 
has no substrate upon which to generate mutants that may 
have a survival advantage. We have tried to exploit this 
advantage further by targeting with HIV-prom-A, a highly 
conserved  region  of  HIV-1,  the  nucleotide  sequence  of 
which appears to have been optimized for efficient gene 
expression (Chen-Park et al, 2002).  In addition to sug-
gesting  a  therapeutic  strategy  for  HIV-1  infection,  our 
findings  demonstrate  that  a  pathway  of  RNA-directed 
silencing and methylation exists in mammalian cells. This 
observation and recently published data strongly suggest 
that, as it has been shown to do in yeast and plants (Hall 
et al, 2002; Verdel et al, 2004), the pathway may maintain 
silent chromatin in  vertebrates (Volpe et al, 2002), and 
may be amenable to the induction of stable silencing of 
other sequences in mammals. 
 
CONCLUSIONS 
 
• siRNAs targeting the promoter region of HIV-1 can in-
duced suppression of viral replication, cytosine methyla-
tion and transcriptional gene silencing. 
 
• The suppression can be durable and the extent of sup-
pression appears to correlate with the density of de novo 
cytosine methylation. 
 
• Although the precise mechanisms involved are unclear, 
DNA methylation appears critical as  demethylation re-
sults in partial reversal of suppression. 
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